Table 1 Patient characteristics, therapy regimen and clinical outcomes of the study cohort
Patient ID | Study Site | Sex | Age at Sampling (years) | Clinical Stage at Sampling | Metagenomics:Stage of Lesions (Body Site) | RT-qPCR: Stage of Lesions (Body Site) | TCRseq:Tissues included | ΔSA- subgroup | Therapy | Event | TTE (months) | Follow-up Time (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pat1 | MZ | f | 81 | IA | Plaque (hip), Patch (forearm) | Plaque (hip) | Skin (Plaque), Blood | positive | PUVA, Mechlorethamine | Yes | 2.60 | 17.56 |
Pat2 | MZ | f | 57 | IB | Plaque (thigh), Plaque (abdomen) | NA | NA | neutral | PUVA, UVB, topical steroids, Pimecrolimus, MTX, Bexarotene, Mogamulizumab | Yes | 18.41 | 18.41 |
Pat3 | MZ | f | 47 | IB | Patch (thigh) | Patch (thigh) | NA | neutral | topical steroids | Censored | Censored | 17.95 |
Pat4 | MZ | m | 70 | IIB | Plaque (upper back),Plaque (flank) | Plaque (upper back) | Skin (Plaque and nonlesional), Blood | positive | topical steroids, Bexarotene, Mogamulizumab, RTx | Yes | 0.92 | 9.99 |
Pat5 | MZ | f | 73 | IB | Patch (thigh),Patch (forearm) | Patch (thigh) | Skin (Patch and nonlesional) | neutral | topical steroids | Yes | 13.87 | 17.10 |
Pat6 | MZ | f | 81 | IA | Patch (breast) | Patch (breast) | Skin (Patch and nonlesional) | neutral | topical steroids, Mechlorethamine | Censored | Censored | 15.55 |
Pat7 | MZ | m | 54 | IB | Patch (forearm), Plaque (flank) | Plaque (flank) | Skin (Plaque and nonlesional) | neutral | PUVA, PEG-IFNα | Censored | Censored | 16.11 |
Pat8 | MZ | m | 82 | IIB | Plaque (head, parietal), Patch (upper back) | Patch (upper back) | Skin (Patch), Blood | positive | topical steroids, MTX, RTx | Yes | 2.53 | 2.53 |
Pat9 | MZ | m | 63 | IB | Plaque (forearm) | Plaque (forearm) | Skin (Plaque) | neutral | Topical steroids, PUVA, RTx | Yes | 6.41 | 14.27 |
Pat10 | MZ | m | 49 | IB | Patch (gluteus right), Patch (gluteus left) | Patch (gluteus left) | Skin (Patch) | neutral | NA | LFU | LFU | LFU |
Pat11 | MZ | m | 61 | IIB | Patch (wrist) | NA | NA | neutral | NA | LFU | LFU | LFU |
Pat12 | MZ | m | 88 | IA | Patch (abdomen), Patch (thigh) | Patch (thigh) | Skin (Patch and nonlesional), Blood | neutral | no special therapy, only moisturizing cremes | Censored | Censored | 11.51 |
Pat13 | MZ | m | 66 | IB | Patch (lower leg, front), Patch (lower leg, back) | Patch (lower leg, back) | NA | neutral | topical steroids | Censored | Censored | 11.51 |
Pat14 | MZ | m | 62 | IB | Plaque (forearm), Plaque (lower leg, front) | Plaque (lower leg, front) | Skin (Plaque and nonlesional), Blood | neutral | topical steroids, Silver iodide | Censored | Censored | 11.05 |
Pat15 | FFM | f | 73 | IB | 2x Plaque (lower leg, front and gluteus) | NA | NA | positive | MTX, RTx | Yes | 2.83 | 11.57 |
Pat16 | FFM | f | 58 | IA | Plaque (scapula) | NA | NA | positive | MTX, Bexarotene | Yes | 4.87 | 11.51 |
Pat17 | FFM | m | 83 | IIB | 2x Patch (hip and rips) | NA | NA | neutral | Bexarotene | Yes | 7.00 | 7.00 |
Pat18 | FFM | f | 61 | IB | 2x Patch (thigh dorsal & abdominal) | NA | NA | neutral | no special therapy | Censored | Censored | 9.99 |
Pat19 | FFM | m | 54 | IIB | Patch (shoulder), Plaque (thigh) | NA | NA | neutral | Bexarotene | Censored | Censored | 9.67 |
Pat20 | FFM | m | 65 | IB | Plaque (forearm) | NA | NA | neutral | Bexarotene | Censored | Censored | 11.11 |
